Celcuity Inc.

11.25
0.04 (0.36%)
At close: Jan 22, 2025, 3:59 PM
11.27
0.18%
After-hours Jan 22, 2025, 04:00 PM EST
undefined%
Bid 10.76
Market Cap 417.71M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.67
PE Ratio (ttm) -4.21
Forward PE n/a
Analyst Buy
Ask 11.76
Volume 135,162
Avg. Volume (20D) 286,871
Open 11.21
Previous Close 11.21
Day's Range 11.00 - 11.91
52-Week Range 10.35 - 22.19
Beta undefined

About CELC

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 55
Stock Exchange NASDAQ
Ticker Symbol CELC

Analyst Forecast

According to 6 analyst ratings, the average rating for CELC stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 140.00% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago
-10.28%
Celcuity shares are trading lower after the compan... Unlock content with Pro Subscription
5 months ago
-2.91%
Celcuity shares are trading lower. The company reported Q2 financial results.